The search for biomarkers in Parkinson’s disease: a critical review

References

• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69, 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Rachakonda V, Pan TH, Le WD. Biomarkers of neurodegenerative disorders: how good are they? Cell Res.14(5), 349–360 (2004).
   Google Scholar
• DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science302(5646), 830–834 (2003).
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain114(Pt 5), 2283–2301 (1991).
   PubMed Web of Science ®Google Scholar
• Brown RG, Marsden CD. Cognitive function in Parkinson’s disease: from description to theory. Trends Neurosci.13(1), 21–29 (1990).
   PubMed Web of Science ®Google Scholar
• Thomas B, Beal MF. Parkinson’s disease. Hum. Mol. Genet.16(Spec No. 2), R183–R194 (2007).
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology68(5), 384–386 (2007).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125, 861–870 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology42, 1142–1146 (1992).
   PubMed Web of Science ®Google Scholar
• Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson’s disease. Brain127(Pt 8), 1693–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor Tavares AL, Jefferis GS, Koop M et al. Quantitative measurements of alternating finger tapping in Parkinson’s disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Mov. Disord.20(10), 1286–1298 (2005).
   PubMed Web of Science ®Google Scholar
• Jobbagy A, Harcos P, Karoly R, Fazekas G. Analysis of finger-tapping movement. J. Neurosci. Methods141(1), 29–39 (2005).
   PubMed Web of Science ®Google Scholar
• Okuno R, Yokoe M, Akazawa K, Abe K, Sakoda S. Finger taps movement acceleration measurement system for quantitative diagnosis of Parkinson’s disease. Conf. Proc. IEEE Eng. Med. Biol. Soc. Suppl., 6623–6626 (2006).
   PubMedGoogle Scholar
• Okuno R, Yokoe M, Fukawa K, Sakoda S, Akazawa K. Measurement system of finger-tapping contact force for quantitative diagnosis of Parkinson’s disease. Conf. Proc. IEEE Eng. Med. Biol. Soc.1354–1357 (2007).
   Google Scholar
• de Frias CM, Dixon RA, Fisher N, Camicioli R. Intraindividual variability in neurocognitive speed: a comparison of Parkinson’s disease and normal older adults. Neuropsychologia45(11), 2499–2507 (2007).
   PubMed Web of Science ®Google Scholar
• Bazner H, Schanz J, Blahak C et al. Differential pattern of hand-tapping compromise in vascular versus idiopathic parkinsonism: a study based on computerized movement analysis. Mov. Disord.20(4), 504–508 (2005).
   PubMedGoogle Scholar
• Accolla E, Caputo E, Cogiamanian F et al. Gender differences in patients with Parkinson’s disease treated with subthalamic deep brain stimulation. Mov. Disord.22(8), 1150–1156 (2007).
   PubMedGoogle Scholar
• Camicioli RM, Wieler M, de Frias CM, Martin WR. Early, untreated Parkinson’s disease patients show reaction time variability. Neurosci. Lett.441(1), 77–80 (2008).
   PubMedGoogle Scholar
• Armstrong IT, Chan F, Riopelle RJ, Munoz DP. Control of saccades in Parkinson’s disease. Brain Cogn.49(2), 198–201 (2002).
   PubMedGoogle Scholar
• MacAskill MR, Anderson TJ, Jones RD. Adaptive modification of saccade amplitude in Parkinson’s disease. Brain125(Pt 7), 1570–1582 (2002).
   PubMed Web of Science ®Google Scholar
• Winograd-Gurvich C, Georgiou-Karistianis N, Fitzgerald PB, Millist L, White OB. Self-paced saccades and saccades to oddball targets in Parkinson’s disease. Brain Res.1106(1), 134–141 (2006).
   PubMed Web of Science ®Google Scholar
• Antoniades CA, Carpenter RS, Barker RA. Diagnostic potential of saccadometry in progressive supranuclear palsy. Biomark. Med.4(1), 487–490 (2007).
   Google Scholar
• Mosimann UP, Muri RM, Burn DJ et al. Saccadic eye movement changes in Parkinson’s disease dementia and dementia with Lewy bodies. Brain128(Pt 6), 1267–1276 (2005).
   PubMed Web of Science ®Google Scholar
• Rivaud-Pechoux S, Vidailhet M, Brandel JP, Gaymard B. Mixing pro- and antisaccades in patients with parkinsonian syndromes. Brain130(Pt 1), 256–264 (2007).
   PubMed Web of Science ®Google Scholar
• Michell AW, Xu Z, Fritz D et al. Saccadic latency distributions in Parkinson’s disease and the effects of L-DOPA. Exp. Brain Res.174(1), 7–18 (2006).
   PubMed Web of Science ®Google Scholar
• Hood AJ, Amador SC, Cain AE et al. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry78(6), 565–570 (2007).
   PubMed Web of Science ®Google Scholar
• Stern MB. The preclinical detection of Parkinson’s disease: ready for prime time? Ann. Neurol.56(2), 169–171 (2004).
   PubMedGoogle Scholar
• Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry62(5), 436–446 (1997).
   PubMed Web of Science ®Google Scholar
• Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J. Chronic Dis.28(9), 493–497 (1975).
   PubMedGoogle Scholar
• Double KL, Rowe DB, Hayes M et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch. Neurol.60(4), 545–549 (2003).
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Lees AJ. Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr. Opin. Neurol.17(4), 417–423 (2004).
   PubMed Web of Science ®Google Scholar
• Kranick SM, Duda JE. Olfactory dysfunction in Parkinson’s disease. Neurosignals16(1), 35–40 (2008).
   PubMedGoogle Scholar
• Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J. Neural Transm.109(5–6), 805–811 (2002).
   PubMed Web of Science ®Google Scholar
• Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. Laryngoscope94(2 Pt 1), 176–178 (1984).
   PubMed Web of Science ®Google Scholar
• Suchowersky O, Reich S, Perlmutter J et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 968–975 (2006).
   PubMed Web of Science ®Google Scholar
• Rothwell JC, Obeso JA, Traub MM, Marsden CD. The behaviour of the long-latency stretch reflex in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry46(1), 35–44 (1983).
   PubMedGoogle Scholar
• Berardelli A, Sabra AF, Hallett M. Physiological mechanisms of rigidity in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry46(1), 45–53 (1983).
   PubMedGoogle Scholar
• Meigal AI, Rissanen S, Tarvainen MP et al. Novel parameters of surface EMG in patients with Parkinson’s disease and healthy young and old controls. J. Electromyogr. Kinesiol. (2008) (Epub ahead of print).
   Google Scholar
• Valkovic P, Krafczyk S, Botzel K. Postural reactions to soleus muscle vibration in Parkinson’s disease: scaling deteriorates as disease progresses. Neurosci. Lett.401(1–2), 92–96 (2006).
   PubMedGoogle Scholar
• Valkovic P, Krafczyk S, Saling M, Benetin J, Botzel K. Postural reactions to neck vibration in Parkinson’s disease. Mov. Disord.21(1), 59–65 (2006).
   PubMed Web of Science ®Google Scholar
• Grasso M, Mazzini L, Schieppati M. Muscle relaxation in Parkinson’s disease: a reaction time study. Mov. Disord.11(4), 411–420 (1996).
   PubMedGoogle Scholar
• Wang L, Kuroiwa Y, Li M et al. The correlation between P300 alterations and regional cerebral blood flow in non-demented Parkinson’s disease. Neurosci. Lett.282(3), 133–136 (2000).
   PubMedGoogle Scholar
• Falkenstein M, Hoormann J, Hohnsbein J. Changes of error-related ERPs with age. Exp. Brain Res.138(2), 258–262 (2001).
   PubMed Web of Science ®Google Scholar
• Valls-Sole J, Valldeoriola F. Neurophysiological correlate of clinical signs in Parkinson’s disease. Clin. Neurophysiol.113(6), 792–805 (2002).
   PubMedGoogle Scholar
• Dubow JS. Autonomic dysfunction in Parkinson’s disease. Dis. Mon.53(5), 265–274 (2007).
   PubMedGoogle Scholar
• Vodusek DB. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov. Disord.16(4), 600–607 (2001).
   PubMedGoogle Scholar
• Valldeoriola F, Valls-Sole J, Tolosa ES, Marti MJ. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov. Disord.10(5), 550–555 (1995).
   PubMedGoogle Scholar
• Libelius R, Johansson F. Quantitative electromyography of the external anal sphincter in Parkinson’s disease and multiple system atrophy. Muscle Nerve23(8), 1250–1256 (2000).
   PubMedGoogle Scholar
• Giladi N, Simon ES, Korczyn AD et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson’s disease. Muscle Nerve23(5), 731–734 (2000).
   PubMedGoogle Scholar
• Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson’s disease. Lancet Neurol.3(5), 284–290 (2004).
   PubMed Web of Science ®Google Scholar
• Piccini P, Brooks DJ. New developments of brain imaging for Parkinson’s disease and related disorders. Mov. Disord.21(12), 2035–2041 (2006).
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson’s disease as revealed by MR imaging. AJNR Am. J. Neuroradiol.21(4), 697–701 (2000).
   PubMed Web of Science ®Google Scholar
• Hu MT, White SJ, Herlihy AH et al. A comparison of (18)F-DOPA PET and inversion recovery MRI in the diagnosis of Parkinson’s disease. Neurology56(9), 1195–1200 (2001).
   PubMedGoogle Scholar
• Minati L, Grisoli M, Carella F et al. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am. J. Neuroradiol.28(2), 309–313 (2007).
   PubMedGoogle Scholar
• Chan LL, Rumpel H, Yap K et al. Case control study of diffusion tensor imaging in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry78(12), 1383–1386 (2007).
   PubMedGoogle Scholar
• Ito M, Watanabe H, Kawai Y et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry78(7), 722–728 (2007).
   PubMed Web of Science ®Google Scholar
• Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J. Neurol.248(8), 684–689 (2001).
   PubMed Web of Science ®Google Scholar
• Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov. Disord.20(3), 383–385 (2005).
   PubMed Web of Science ®Google Scholar
• Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson’s disease. Mov. Disord.21(1), 94–98 (2006).
   PubMedGoogle Scholar
• Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound. J. Neurol. Neurosurg. Psychiatry76(3), 423–425 (2005).
   PubMed Web of Science ®Google Scholar
• Walter U, Dressler D, Probst T et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch. Neurol.64(11), 1635–1640 (2007).
   PubMedGoogle Scholar
• Stockner H, Sojer M, K KS et al. Midbrain sonography in patients with essential tremor. Mov. Disord.22(3), 414–417 (2007).
   PubMed Web of Science ®Google Scholar
• Seibyl JP, Marek KL, Quinlan D et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann. Neurol.38(4), 589–598 (1995).
   PubMed Web of Science ®Google Scholar
• Pirker W, Djamshidian S, Asenbaum S et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov. Disord.17(1), 45–53 (2002).
   PubMed Web of Science ®Google Scholar
• Winogrodzka A, Bergmans P, Booij J et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J. Neural Transm.108(8–9), 1011–1019 (2001).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Ichise M, Ballinger JR et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov. Disord.17(2), 303–312 (2002).
   PubMed Web of Science ®Google Scholar
• Vlaar AM, de Nijs T, Kessels AG et al. Diagnostic value of I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur. Neurol.59(5), 258–266 (2008).
   PubMed Web of Science ®Google Scholar
• Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson’s disease progression? Eur. J. Neurol.9(Suppl. 3), 15–22 (2002).
   PubMed Web of Science ®Google Scholar
• Eckert T, Feigin A, Lewis DE et al. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov. Disord.22(2), 167–173 (2007).
   PubMed Web of Science ®Google Scholar
• Ravina B, Eidelberg D, Ahlskog JE et al. The role of radiotracer imaging in Parkinson disease. Neurology64(2), 208–215 (2005).
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Technology insight: imaging neurodegeneration in Parkinson’s disease. Nat. Clini. Pract.4(5), 267–277 (2008).
   PubMedGoogle Scholar
• Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson’s disease. Ann. Neurol.53(2), 206–213 (2003).
   PubMed Web of Science ®Google Scholar
• A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol.23(1), 34–44 (2000).
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol.54(1), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Burn DJ, Mark MH, Playford ED et al. Parkinson’s disease in twins studied with 18F-Dopa and positron emission tomography. Neurology42(10), 1894–1900 (1992).
   PubMed Web of Science ®Google Scholar
• Laihinen A, Ruottinen H, Rinne JO et al. Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J. Neurol.247(Suppl. 2), II110–II113 (2000).
   PubMedGoogle Scholar
• Bruck A, Aalto S, Nurmi E et al. Striatal subregional 6-[18F]fluoro-L-DOPA uptake in early Parkinson’s disease: a two-year follow-up study. Mov. Disord.21(7), 958–963 (2006).
   PubMedGoogle Scholar
• Wang J, Zuo CT, Jiang YP et al.18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn and Yahr stages. J. Neurol.254(2), 185–190 (2007).
   PubMedGoogle Scholar
• Nurmi E, Ruottinen HM, Bergman J et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov. Disord.16(4), 608–615 (2001).
   PubMed Web of Science ®Google Scholar
• Martin WR, Wieler M, Stoessl AJ, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson’s disease. Ann. Neurol.63(3), 388–394 (2008).
   PubMedGoogle Scholar
• Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci.19(8), 312–318 (1996).
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Sekine Y et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann. Neurol.57(2), 168–175 (2005).
   PubMed Web of Science ®Google Scholar
• Gerhard A, Pavese N, Hotton G et al.In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis.21(2), 404–412 (2006).
   PubMed Web of Science ®Google Scholar
• Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov. Disord.18(8), 890–897 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Li ST et al. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med.133(5), 338–347 (2000).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Spiegel J, Hellwig D, Farmakis G et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease. Mov. Disord.22(7), 1004–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Orimo S, Takahashi A, Uchihara T et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol.17(1), 24–30 (2007).
   PubMed Web of Science ®Google Scholar
• Quattrone A, Bagnato A, Annesi G et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson’s disease. Mov. Disord.23(1), 21–27 (2008).
   PubMedGoogle Scholar
• Spiegel J, Mollers MO, Jost WH et al. FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov. Disord.20(5), 552–561 (2005).
   PubMedGoogle Scholar
• Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica29(11), 1181–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Wilson ID. Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat. Rev.2(8), 668–676 (2003).
   Google Scholar
• Holmes E, Tsang TM, Tabrizi SJ. The application of NMR-based metabonomics in neurological disorders. NeuroRx3(3), 358–372 (2006).
   PubMedGoogle Scholar
• Underwood BR, Broadhurst D, Dunn WB et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain129(Pt 4), 877–886 (2006).
   PubMed Web of Science ®Google Scholar
• Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in Parkinson’s disease. Metabolomics4(3), 191–201 (2008).
   Google Scholar
• Bogdanov M, Matson WR, Wang L et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain131(Pt 2), 389–396 (2008).
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM et al. α-synuclein in Lewy bodies. Nature388(6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Michell AW, Luheshi LM, Barker RA. Skin and platelet α-synuclein as peripheral biomarkers of Parkinson’s disease. Neurosci. Lett.381(3), 294–298 (2005).
   PubMed Web of Science ®Google Scholar
• Li QX, Campbell BC, McLean CA et al. Platelet α- and γ-synucleins in Parkinson’s disease and normal control subjects. J. Alzheimers Dis.4(4), 309–315 (2002).
   PubMedGoogle Scholar
• El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J.20(3), 419–425 (2006).
   PubMed Web of Science ®Google Scholar
• Tokuda T, Salem SA, Allsop D et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Comm.349(1), 162–166 (2006).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol.213(2), 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T. Platelet monoamine oxidase B and plasma β-phenylethylamine in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry70(2), 229–231 (2001).
   PubMed Web of Science ®Google Scholar
• Trimmer PA, Swerdlow RH, Parks JK et al. Abnormal mitochondrial morphology in sporadic Parkinson’s and Alzheimer’s disease cybrid cell lines. Exp. Neurol.162(1), 37–50 (2000).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Ohta S, Tanaka M et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem. Biophys. Res. Comm.163(3), 1450–1455 (1989).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Mann VM, Cooper JM et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J. Neurochem.55(6), 2142–2145 (1990).
   PubMed Web of Science ®Google Scholar
• Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann. Neurol.26(6), 719–723 (1989).
   PubMed Web of Science ®Google Scholar
• Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci.26(19), 5256–5264 (2006).
   PubMed Web of Science ®Google Scholar
• Esteves AR, Domingues AF, Ferreira IL et al. Mitochondrial function in Parkinson’s disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion8(3), 219–228 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol.129(4), 526–529 (2008).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Steinacker P, Bahn E et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener. Dis.4(5), 366–375 (2007).
   PubMed Web of Science ®Google Scholar
• Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol. Aging28(5), 742–747 (2007).
   PubMed Web of Science ®Google Scholar
• Molina JA, Benito-Leon J, Jimenez-Jimenez FJ et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson’s disease patients. Neurosci. Lett.238(3), 139–141 (1997).
   PubMed Web of Science ®Google Scholar
• Shalon D, Smith SJ, Brown PO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res.6(7), 639–645 (1996).
   PubMed Web of Science ®Google Scholar
• Hauser MA, Li YJ, Xu H et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch. Neurol.62(6), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Anantharam V, Lehrmann E, Kanthasamy A et al. Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson’s disease. Neurochem. Int.50(6), 834–847 (2007).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Eklund AC, Morse LJ et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc. Natl Acad. Sci. USA104(3), 955–960 (2007).
   PubMed Web of Science ®Google Scholar
• Hennecke G, Scherzer CR. RNA biomarkers of Parkinson’s disease: developing tools for novel therapies. Biomark. Med.2(1), 41–53 (2008).
   PubMedGoogle Scholar